Go figure! STJ has moved up 25% while BSX has remained flat, despite crappy STJ Riata issues. BSX will be taking market share from STJ due to impact from Riata issue hanging over STJ's other products. JNJ droppin their stent business in addition to new BSX defibrillator and stent products, this should be a great year for BSX.
I agree that Riata is going to be a problem for STJ, and it'll be big problem.
However, the Quartet lead is opening a lot of doors for them that were previously closed. In the near term, Quartet will probably cause STJ to take market share from BSX and MDT. After Riata/Durata explodes in their face, who knows? It's not about the tachy leads, it's about the tachy cans. Maybe you'll see STJ cans with Quartet and BSX or MDT defib lead. Or maybe STJ will pick up biotronik's defib lead, rebrand it, and at it to their rep's bags. (I think the industry phrase for this is pulling a Dextrus.)
if its down prior to earnings on low volume then normally the news will be good and we get a spike up more than a dollar. If the volume is high then the spike will come prior to earnings and sell off after earnings and most likely the street will have every excuse in the world why it should drop. UNLESS its amazing and it surprises the street then look out it will rock and roll.